Skip to main content

Advertisement

SpringerLink
Log in

Effects of infliximab on sister chromatid exchanges and chromosomal aberration in patients with rheumatoid arthritis

  • Original Research
  • Published:
Cytotechnology Aims and scope Submit manuscript

Abstract

The aim of this study was to evaluate in a 24-weeks the effect of anti-TNF-alpha, infliximab, on cytogenetic biomarkers in peripheral lymphocytes of patients with rheumatoid arthritis (RA). A total of 40 patients with RA met the criteria to be treated with methotrexate (15 mg/week) were evaluated. Twenty patients, randomly selected, were treated with infliximab in addition to methotrexate (group I), whereas the other 20 patients continued with only methotrexate treatment (group M). Twenty healthy volunteers matched for age, gender and smoking habits served as control group (group C). At baseline, sister chromatid exchange rate was 7.20 ± 2.21 in group I, 7.40 ± 1.60 in group M and 4.97 ± 1.32 in group C (P < 0.01 vs group I and M). After 24-weeks, sister chromatid exchange rate was 7.87 ± 2.54 in group I and 7.81 ± 1.95 in group M (P = ns). High frequency cells count was 4.9 % and 4.7 % in the groups I and M, respectively, at the end of the study (P = ns). The basal chromosomal aberration frequency was 4.90 % in group I and 5.20 % in groups M; after 24-weeks, this was 5.10 % in group I and 5.10 % in groups M (P = ns). Infliximab treatment, for 24 weeks, did not increase the cytogenetic biomarkers in patients with RA. Our data show that the use of infliximab has not a genotoxic effect in patients with RA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Albertini RJ, Anderson D, Douglas GR, Hagmar L, Hemminki K, Merlo F, Natarajan AT, Norppa H, Shuker DE, Tice R, Waters MD, Aitio A (2000) IPCS guidelines for the monitoring of genotoxic effects of carcinogens in humans. International Programme on Chemical Safety. Mutat Res 463:111–172

    Article  CAS  Google Scholar 

  • Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324

  • Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D (2011) Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 20:119–130

    Article  CAS  Google Scholar 

  • Balkwill F (2006) TNF-α in promotion and progression of cancer. Cancer Metastasis Res 25:409–416

    Article  CAS  Google Scholar 

  • Carrano AV, Moore DH (1982) The rationale and methodology for quantifying sister chromatid exchange in humans. In: Heddle JA (ed) New horizons in genetic toxicology. Academic Press, New York, pp 267–304

    Google Scholar 

  • Cottliar A, Fundia A, Boerr L, Sambuelli A, Negreira S, Gil A, Gómez JC, Chopita N, Bernedo A, Slavutsky I (2000) High frequencies of telomeric associations, chromosome aberrations, and sister chromatid exchanges in ulcerative colitis. Am J Gastroenterol 95:2301–2307

  • Demirkaya E, Cok I, Durmaz E, Ulutas OK, Ayaz NA, Besbas N, Ozen S (2010) Genotoxicity of anti-tumor necrosis factor therapy in patients with juvenile idiopathic arthritis. Arthritis Care Res 62:73–77

  • Esser AC, Abril A, Fayne S, Doyle JA (2004) Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. J Am Acad Dermatol 50:S75–S77

    Article  Google Scholar 

  • Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, Hoover R, Fraumeni JF Jr (1993) Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85:307–311

  • National Institute of Clinical Excellence (2002) Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. Technology appraisal guidance, March 2002, no. 36. National Institute of Clinical Excellence, London

  • Hagmar L, Strömberg U, Bonassi S, Hansteen IL, Knudsen LE, Lindholm C, Norppa H (2004) Impact of types of lymphocyte chromosomal aberrations on human cancer risk: results from Nordic and Italian cohorts. Cancer Res 64:2258–2263

  • Kageyama Y, Takahashi M, Ichikawa T, Torikai E, Nagano A (2008) Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis. Clin Exp Rheumatol 26:73–80

    CAS  Google Scholar 

  • Kang MH, Genser D, Elmadfa I (1997) Increased sister chromatid exchanges in peripheral lymphocytes of patients with Crohn’s disease. Mutat Res 381:141–148

    Article  CAS  Google Scholar 

  • Latt SA (1981) Sister chromatid exchanges formation. Annu Rev Genet 15:11–55

    Article  CAS  Google Scholar 

  • McCarthy CJ, Sheldon S, Ross CW, McCune WJ (1998) Cytogenetic abnormalities and therapy-related myelodysplastic syndromes in rheumatic disease. Arthritis Rheum 41:1493–1496

    Article  CAS  Google Scholar 

  • Mellemkjaer L, Linet MS, Gridley G, Frisch M, Møller H, Olsen JH (1996) Rheumatoid arthritis and cancer risk. Eur J Cancer 32A:1753–1757

    Article  CAS  Google Scholar 

  • Munshi NC, Diqumarthy S, Rahemtullah A (2008) Case records of the Massachusetts General Hospital: case 13-2008. A 46-year-old man with rheumatoid arthritis and lymphadenopathy. N Engl J Med 358:1838–1848

    Article  CAS  Google Scholar 

  • Palmer RG, Dore CJ, Henderson L, Denman AM (1987) Sister-chromatid exchange frequencies in fibroblasts and lymphocytes of patients with systemic lupus erythematosus. Mutat Res 177:125–132

    Article  CAS  Google Scholar 

  • Perkins ND (2004) NF-κB: tumor promoter or suppressor? Trends Cell Biol 14:64–69

    Article  CAS  Google Scholar 

  • Ramos-Remus C, Dorazco-Barragan G, Aceves-Avila FJ, Alcaraz-Lopez F, Fuentes-Ramirez F, Michel-Diaz J, Torres-Bugarin O, Ventura-Aguilar A, Zuñiga-González G (2002) Genotoxicity assessment using micronuclei assay in rheumatoid arthritis patients. Clin Exp Rheumatol 20:208–212

  • Rantapää Dahlqvist S, Nordenson I (1996) Chromosomal changes in rheumatoid arthritis patients treated with CPH82. Clin Rheumatol 15:584–589

    Article  Google Scholar 

  • Russel PJ (2002) Chromosomal mutations. In: Cummings B (ed) Genetics. Pearson Educations Inc, San Francisco, pp 595–621

    Google Scholar 

  • Shahin AA, Ismail MM, Saleh AM, Moustafa HA, Aboul-Ella AA, Gabr HM (2001) Protective effect of folinic acid on low-dose methotrexate genotoxicity. Z Rheumatol 60:63–68

    Article  CAS  Google Scholar 

  • Thomas E, Brewster DH, Black RJ, Macfarlane GJ (2000) Risk of malignancy among patients with rheumatic conditions. Int J Cancer 88:497–502

    Article  CAS  Google Scholar 

  • Van Horssen R, Ten Hagen TL, Eggermont AM (2006) TNF-α in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 11:397–408

    Article  Google Scholar 

  • Verma RS, Babar A (1989) Sister chromatid differentiation. In: Verma RS, Babar A (eds) Human chromosomes manual of basic techniques. Pergamon, New York, pp 124–131

    Google Scholar 

  • Wolff S, Perry P (1974) Differential Giemsa staining of sister chromatid and the study of chromatid exchange in human. Chromosoma 48:341–353

    Article  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Clinical and Experimental Medicine, University of Messina, Pad. C, 3rd floor, A.O.U. Policlinico “G. Martino” Via C. Valeria, 98125, Messina, Italy

    M. Atteritano, S. Mazzaferro, S. Mantuano, G. L. Bagnato & G. F. Bagnato

Authors
  1. M. Atteritano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Mazzaferro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Mantuano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. L. Bagnato
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. F. Bagnato
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Atteritano.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Atteritano, M., Mazzaferro, S., Mantuano, S. et al. Effects of infliximab on sister chromatid exchanges and chromosomal aberration in patients with rheumatoid arthritis. Cytotechnology 68, 313–318 (2016). https://doi.org/10.1007/s10616-014-9782-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10616-014-9782-4

Keywords

Search

Navigation